Trial Profile
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Olverembatinib (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 17 Mar 2024 Planned number of patients changed from 60 to 100.
- 24 Oct 2023 Planned End Date changed from 31 Mar 2024 to 31 Dec 2026.
- 24 Oct 2023 Planned primary completion date changed from 30 Sep 2023 to 31 Dec 2024.